The Pain Management Devices Market, estimated at USD 4,855.7 Mn in 2025, is expected to exhibit a CAGR of 6.5% and reach USD 7,545.7 Mn by 2032.
The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.
One of the key drivers of market expansion is U.S. FDA (U.S. Food and Drug Administration) approval, as this promotes rapid adaptation. For example, in September 2025, DyAnsys Inc., a medical device company specializing in the autonomous nervous system, announced Primary Relief, its percutaneous electrical nerve stimulator (PENS) system, received approval by the FDA to treat postoperative pain following cardiac surgery. According to DyAnsys, the PENS system can be used for up to three days following cardiac surgery and, in a clinical trial, reduced pain scores compared to a placebo device and the need for analgesics postoperatively. The company also notes fentanyl use by the Primary Relief group in the postoperative period was one-third of the control group.
Global Pain Management Devices Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of drugs from one place to another.
COVID-19 had a positive impact on the global pain management devices market. For instance, according to an article published in Nature in April 2025, the finding indicated that pain ratings remained unchanged among patients after the pandemic onset. However, pain catastrophizing scores were elevated when COVID-19 cases peaked in July 2025. Pain interference, physical function, sleep impairment, and emotional support were improved in the post-COVID-19 cohort. Depression, anxiety, anger, and social isolation remained unchanged.
Global Pain Management Devices Market: Key Developments
Additionally, awareness related to the pain management, are expected to boost market growth during the forecast period. For instance, on February 23, 2025, Pacira BioSciences, Inc., a company committed to non-opioid pain management and regenerative health solutions, and the Ladies Professional Golf Association (LPGA), announced a multi-year sponsorship that makes Pacira’s iovera, a handheld medical device that provides non-medicated pain control by applying cold therapy to a specific nerve to interrupt its ability to transmit a pain signal.